Dr. Paul Stoffels is Chief Scientific Officer, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee.
Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson& Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology. Additionally, Paul has oversight for product safety of all products of the Johnson & Johnson Family of Companies worldwide.
Paul also is Worldwide Chairman of Janssen Pharmaceutical Companies of Johnson & Johnson, with responsibility for expansion of the company’s therapeutic pipeline through global R&D and strategic partnerships, licensing and acquisitions. He leads teams across Janssen to discover and develop treatments for unmet medical needs in the therapeutic areas of cardiovascular & metabolism, immunology, infectious disease &vaccines, neuroscience and oncology.
Prior to his role as Worldwide Chairman, he served as Global Head, Johnson & Johnson Pharmaceutical R&D from 2009 – 2011, as Company Group Chairman, Central Nervous System & Internal Medicine, from 2006 – 2009, and as Company Group Chairman, Global Virology, from 2005-2006. Paul joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of a number of leading products for the treatment of HIV.
Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.